Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

115
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
115
Hazard Ratio01:12

Hazard Ratio

79
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
79
Testing a Claim about Population Proportion01:24

Testing a Claim about Population Proportion

3.3K
A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
3.3K
Prediction Intervals01:03

Prediction Intervals

2.2K
The interval estimate of any variable is known as the prediction interval. It helps decide if a point estimate is dependable.
However, the point estimate is most likely not the exact value of the population parameter, but close to it. After calculating point estimates, we construct interval estimates, called confidence intervals or prediction intervals. This prediction interval comprises a range of values unlike the point estimate and is a better predictor of the observed sample value, y. 
2.2K
Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

174
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
174

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases: Temporal Trends in Sweden and France (2003-2022).

Neurology·2026
Same author

Alzheimer's disease.

Lancet (London, England)·2026
Same author

How to improve statistical power in a trial with SCA2 patients using natural history data.

Trials·2026
Same author

Association of infections and autoimmune conditions with cognition: a study using self-reported conditions and identifying a novel plasma biomarker.

medRxiv : the preprint server for health sciences·2026
Same author

Value of MRI Outcomes for Preventive and Early-Stage Trials in Spinocerebellar Ataxias 1 and 3.

Annals of clinical and translational neurology·2026
Same author

Quantifying Placebo Effects in Hereditary Ataxia Trials: A Meta-Analysis of Scale for the Assessment and Rating of Ataxia (SARA) Score Changes.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Predicting Chemotherapy Response from Staging Laparoscopy Images.

medRxiv : the preprint server for health sciences·2026
Same journal

Development and External Validation of a Machine Learning Model for 10-Year Ischemic Stroke Risk Prediction in Diverse Populations.

medRxiv : the preprint server for health sciences·2026
Same journal

MCH-Guard: Multimodal Machine Learning Framework for Risk Stratification of Cerebral Microhemorrhage Risk in the Alzheimer's Disease Neuroimaging Initiative.

medRxiv : the preprint server for health sciences·2026
Same journal

Genetic and maternal environmental contributions to estimated fetal weight at 20 weeks gestation compared with birthweight.

medRxiv : the preprint server for health sciences·2026
Same journal

Better immediate declarative memory is associated with forgetting during locomotor adaptation in chronic stroke and in older adults.

medRxiv : the preprint server for health sciences·2026
Same journal

An empirical Bayes framework for burden and dispersion association tests helps prioritize rare variants associated with Alzheimer's disease.

medRxiv : the preprint server for health sciences·2026
See all related articles

Related Experiment Video

Updated: May 30, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K

Prediction-powered Inference for Clinical Trials: application to linear covariate adjustment.

Pierre-Emmanuel Poulet1,2,3, Maylis Tran1,2,3, Sophie Tezenas du Montcel1,2,3

  • 1ARAMIS, Sorbonne Université, Paris Brain Institute (ICM Institut du Cerveau), INRIA, INSERM, AP-HP, Groupe Hospitalier Sorbonne Université, Paris, France.

Medrxiv : the Preprint Server for Health Sciences
|January 27, 2025
PubMed
Summary
This summary is machine-generated.

Prediction-powered inference (PPI) enhances clinical trials by creating digital twins for patients, reducing sample size and control group needs. This method leverages machine learning for statistically valid treatment effect estimation.

More Related Videos

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.0K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K

Related Experiment Videos

Last Updated: May 30, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.0K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K

Area of Science:

  • Biostatistics
  • Clinical Trials
  • Machine Learning

Background:

  • Traditional statistical estimation methods in clinical trials can be inefficient.
  • Leveraging machine learning for prediction-powered inference (PPI) offers a novel approach.
  • Existing PPI methods can be enhanced for clinical trial applications.

Purpose of the Study:

  • To introduce and evaluate Prediction-Powered Inference Plus Plus (PPI++) in the context of clinical trials.
  • To demonstrate how PPI++ can provide statistically valid treatment effect estimates.
  • To explore the implications of PPI++ for optimizing clinical trial design and resource allocation.

Main Methods:

  • Utilizing disease progression models to generate prognostic scores for participants based on baseline covariates.
  • Applying the PPI paradigm to create 'digital twins' of treated patients for comparison with untreated controls.
  • Conducting theoretical analysis of the estimator's properties, including asymptotic unbiasedness and variance derivation.
  • Performing simulations to validate the theoretical findings.

Main Results:

  • The proposed PPI++ estimator is asymptotically unbiased for the Average Treatment Effect.
  • An explicit formula for the variance of the PPI++ estimator has been derived.
  • Simulations confirm the theoretical properties and practical utility of the method.
  • Application to an Alzheimer's disease clinical trial indicates significant sample size reduction potential.

Conclusions:

  • PPI++ offers a statistically valid method to incorporate machine learning predictions into clinical trial analysis.
  • This approach can lead to more efficient clinical trials, requiring smaller sample sizes and fewer controls.
  • PPI++ facilitates the direct application of large-scale disease prediction models to clinical trial settings.
  • The method holds promise for improving the efficiency and feasibility of clinical research, particularly in complex diseases like Alzheimer's.